TB Bacteria Hijack Host Protein ECSIT to Shut Down Macrophage Self-Cleaning

Tuberculosis remains a leading infectious killer worldwide, with 8.2 million new cases and 1.25 million deaths recorded in 2023. A particularly difficult challenge is latent TB infection (LTBI), in which Mtb hides silently inside macrophages for years before potentially reactivating. Understanding exactly how the bacterium subverts host immune defenses is critical for developing better therapies, especially as drug-resistant strains continue to spread.

This study focused on HBHA (heparin-binding hemagglutinin), a well-known Mtb virulence factor previously linked to LTBI and autophagy suppression, but whose precise molecular mechanism was unknown. Using a HuProt™ human proteome microarray, the researchers identified ECSIT (evolutionarily conserved signaling intermediate in Toll pathways) as a direct binding partner of HBHA. ECSIT normally sits at the crossroads of TLR/NF-κB immune signaling and mitophagy, making it a high-value target for pathogen exploitation.

Co-immunoprecipitation experiments in BCG-infected RAW264.7 macrophages showed that HBHA binds ECSIT in a dose-dependent manner, physically displacing TRAF6 from the ECSIT complex and dramatically reducing ECSIT ubiquitination. This disruption was more pronounced in BCG-infected cells, suggesting that active bacterial infection amplifies the interaction. Western blot and immunofluorescence analyses confirmed that HBHA suppresses starvation-induced autophagy markers LC3-II and Beclin-1, as well as LC3 puncta formation, in wild-type macrophages. Critically, ECSIT-knockdown macrophages were completely resistant to HBHA's autophagy-suppressing effects — LC3-II conversion and Beclin-1 levels remained unchanged regardless of HBHA concentration — while the autophagy inhibitor 3-MA still worked normally, ruling out a general autophagy defect.

Functional survival assays provided the clearest evidence of biological relevance: HBHA significantly increased intracellular BCG colony counts in wild-type RAW264.7 macrophages in a dose-dependent fashion, but had no significant effect on bacterial survival in ECSIT-knockdown cells. This establishes ECSIT not merely as a binding target but as an indispensable mediator of HBHA's pro-persistence activity.

Taken together, the study reveals a previously unknown mechanism by which Mtb weaponizes its surface adhesin HBHA to hijack host ECSIT, dismantling the ECSIT-TRAF6 ubiquitination axis and crippling autophagic clearance. The HBHA-ECSIT axis represents a compelling new node for host-directed therapeutic strategies aimed at eliminating latent Mtb reservoirs and potentially slowing the emergence of drug resistance.